oru.sePublikationer
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
BETA
Publikationer (10 of 22) Visa alla publikationer
Holster, S., Hooiveld, G. J., Repsilber, D., de Vos, W., Brummer, R. J. & König, J. (2019). Allogenic Faecal Microbiota Transfer Induces Immune-Related Gene Sets in the Colon Mucosa of Patients with Irritable Bowel Syndrome. Biomolecules, 9(10), Article ID 586.
Öppna denna publikation i ny flik eller fönster >>Allogenic Faecal Microbiota Transfer Induces Immune-Related Gene Sets in the Colon Mucosa of Patients with Irritable Bowel Syndrome
Visa övriga...
2019 (Engelska)Ingår i: Biomolecules, E-ISSN 2218-273X, Vol. 9, nr 10, artikel-id 586Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Faecal microbiota transfer (FMT) consists of the introduction of new microbial communities into the intestine of a patient, with the aim of restoring a disturbed gut microbiota. Even though it is used as a potential treatment for various diseases, it is unknown how the host mucosa responds to FMT. This study aims to investigate the colonic mucosa gene expression response to allogenic (from a donor) or autologous (own) FMT in patients with irritable bowel syndrome (IBS). In a recently conducted randomised, double-blinded, controlled clinical study, 17 IBS patients were treated with FMT by colonoscopy. RNA was isolated from colonic biopsies collected by sigmoidoscopy at baseline, as well as two weeks and eight weeks after FMT. In patients treated with allogenic FMT, predominantly immune response-related gene sets were induced, with the strongest response two weeks after the FMT. In patients treated with autologous FMT, predominantly metabolism-related gene sets were affected. Furthermore, several microbiota genera showed correlations with immune-related gene sets, with different correlations found after allogenic compared to autologous FMT. This study shows that the microbe–host response is influenced by FMT on the mucosal gene expression level, and that there are clear differences in response to allogenic compared to autologous FMT.

Ort, förlag, år, upplaga, sidor
MDPI, 2019
Nyckelord
Faecal microbiota transfer, Faecal microbiota transplantation, irritable bowel syndrome, gene expression, gut microbiota, host-microbe interaction
Nationell ämneskategori
Medicin och hälsovetenskap Gastroenterologi
Forskningsämne
Medicin
Identifikatorer
urn:nbn:se:oru:diva-77171 (URN)10.3390/biom9100586 (DOI)31597320 (PubMedID)
Tillgänglig från: 2019-10-10 Skapad: 2019-10-10 Senast uppdaterad: 2019-10-11Bibliografiskt granskad
Edebol-Carlman, H., Rode, J., König, J., Hutchinson, A., Repsilber, D., Kiselev, A., . . . Brummer, R. J. (2019). Evaluating the effects of probiotic intake on brain activity during an emotional attention task and blood markers related to stress in healthy subjects. In: : . Paper presented at Mind, Mood & Microbes, 2nd International Conference on Microbiota-Gut-Brain Axis, Amsterdam, The Netherlands, 17-18 January, 2019.
Öppna denna publikation i ny flik eller fönster >>Evaluating the effects of probiotic intake on brain activity during an emotional attention task and blood markers related to stress in healthy subjects
Visa övriga...
2019 (Engelska)Konferensbidrag, Muntlig presentation med publicerat abstract (Refereegranskat)
Nationell ämneskategori
Biokemi och molekylärbiologi
Identifikatorer
urn:nbn:se:oru:diva-73848 (URN)
Konferens
Mind, Mood & Microbes, 2nd International Conference on Microbiota-Gut-Brain Axis, Amsterdam, The Netherlands, 17-18 January, 2019
Tillgänglig från: 2019-04-17 Skapad: 2019-04-17 Senast uppdaterad: 2019-04-17Bibliografiskt granskad
Holster, S., Lindqvist, C. M., Repsilber, D., Salonen, A., de Vos, W., König, J. & Brummer, R. J. (2019). The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clinical and Translational Gastroenterology, 10(4), Article ID e00034.
Öppna denna publikation i ny flik eller fönster >>The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study
Visa övriga...
2019 (Engelska)Ingår i: Clinical and Translational Gastroenterology, ISSN 2155-384X, E-ISSN 2155-384X, Vol. 10, nr 4, artikel-id e00034Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

OBJECTIVES: Fecal microbiota transfer (FMT) is suggested as a potential treatment for patients with irritable bowel syndrome (IBS). We aimed to study the effect of allogenic and autologous FMT on IBS symptoms, visceral sensitivity, and compositional changes in fecal and mucosa-adherent microbiota.

METHODS: Seventeen patients with IBS were randomized either to receive fecal material from a healthy donor (allogenic) or to receive their own fecal material (autologous). The fecal material was administered into the cecum by whole colonoscopy after bowel cleansing.

RESULTS: No significant differences were found between the allogenic and the autologous FMT regarding symptom scores. However, symptom scores of patients receiving allogenic fecal material significantly decreased after FMT compared with baseline (P 5 0.02), which was not the case in the autologous group (P50.16). Visceral sensitivity was not affected except for a small beneficial effect on urge scores in the autologous group (P < 0.05). While both fecal and mucosa-adherent microbiota of some patients shifted to their respective donor’s fecal microbiota, some patients showed no relevant microbial changes after allogenic FMT. Large compositional shifts in fecal and mucosa-adherent microbiota also occurred in the autologous group.

CONCLUSIONS: This study showed that a single FMT by colonoscopy may have beneficial effects in IBS; however, the allogenic fecal material was not superior to the autologous fecal material. This suggests that bowel cleansing prior to the colonoscopy and/or processing of the fecal material as part of the FMT routine contribute to symptoms and gut microbiota composition changes in IBS.

Ort, förlag, år, upplaga, sidor
Nature Publishing Group, 2019
Nationell ämneskategori
Gastroenterologi
Forskningsämne
Medicin
Identifikatorer
urn:nbn:se:oru:diva-74035 (URN)10.14309/ctg.0000000000000034 (DOI)000466787000001 ()31009405 (PubMedID)
Forskningsfinansiär
Stiftelsen Svensk Näringsforskning
Anmärkning

Funding Agencies:

SIAM Gravitation Grant  024.002.002 

Spinoza 2008 Award of the Netherlands Organization for Scientific Research (NWO) 

Tillgänglig från: 2019-05-06 Skapad: 2019-05-06 Senast uppdaterad: 2019-06-19Bibliografiskt granskad
König, J. & Brummer, R. J. (2018). Is an enzyme supplement for celiac disease finally on the cards?. Expert Review of Gastroenterology & Hepatology, 12(6), 531-533
Öppna denna publikation i ny flik eller fönster >>Is an enzyme supplement for celiac disease finally on the cards?
2018 (Engelska)Ingår i: Expert Review of Gastroenterology & Hepatology, ISSN 1747-4124, E-ISSN 1747-4132, Vol. 12, nr 6, s. 531-533Artikel i tidskrift, Editorial material (Refereegranskat) Published
Ort, förlag, år, upplaga, sidor
Taylor & Francis Group, 2018
Nyckelord
Celiac disease, gluten, gluten-degrading enzymes, non-celiac gluten sensitivity
Nationell ämneskategori
Gastroenterologi
Identifikatorer
urn:nbn:se:oru:diva-66913 (URN)10.1080/17474124.2018.1473762 (DOI)000435679100001 ()29730969 (PubMedID)2-s2.0-85046827101 (Scopus ID)
Tillgänglig från: 2018-05-11 Skapad: 2018-05-11 Senast uppdaterad: 2019-03-26Bibliografiskt granskad
König, J., Holster, S., Bruins, M. & Brummer, R. J. (2017). Aspergillus Niger-Derived Enzyme Degrades Gluten in the Stomach of Gluten-Sensitive Subjects. In: 2017 DDW Abstracts: . Paper presented at Digestive Disease Week (DDW), Chicago, IL, USA, May 6-9, 2017 (pp. S481-S481). Saunders Elsevier, 152(5)
Öppna denna publikation i ny flik eller fönster >>Aspergillus Niger-Derived Enzyme Degrades Gluten in the Stomach of Gluten-Sensitive Subjects
2017 (Engelska)Ingår i: 2017 DDW Abstracts, Saunders Elsevier, 2017, Vol. 152, nr 5, s. S481-S481Konferensbidrag, Muntlig presentation med publicerat abstract (Övrigt vetenskapligt)
Ort, förlag, år, upplaga, sidor
Saunders Elsevier, 2017
Serie
Gastroenterology, ISSN 0016-5085, E-ISSN 1528-0012
Nationell ämneskategori
Gastroenterologi
Identifikatorer
urn:nbn:se:oru:diva-66299 (URN)10.1016/S0016-5085(17)31796-1 (DOI)000403140302008 ()
Konferens
Digestive Disease Week (DDW), Chicago, IL, USA, May 6-9, 2017
Tillgänglig från: 2018-04-03 Skapad: 2018-04-03 Senast uppdaterad: 2019-05-06Bibliografiskt granskad
König, J., Siebenhaar, A., Högenauer, C., Arkkila, P., Nieuwdorp, M., Norén, T., . . . Brummer, R. J. (2017). Consensus report: Faecal microbiota transfer - clinical applications and procedures. Alimentary Pharmacology and Therapeutics, 45(2), 222-239
Öppna denna publikation i ny flik eller fönster >>Consensus report: Faecal microbiota transfer - clinical applications and procedures
Visa övriga...
2017 (Engelska)Ingår i: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 45, nr 2, s. 222-239Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication.

Aim: To provide an expert consensus on current clinical indications, applications and methodological aspects of FMT.

Methods: Well-acknowledged experts from various countries in Europe have contributed to this article. After literature review, consensus has been achieved by repetitive circulation of the statements and the full manuscript among all authors with intermittent adaptation to comments (using a modified Delphi process). Levels of evidence and agreement were rated according to the GRADE system. Consensus was defined a priori as agreement by at least 75% of the authors.

Results: Key recommendations include the use of FMT in recurrent C. difficile infection characterised by at least two previous standard treatments without persistent cure, as well as its consideration in severe and severe-complicated C. difficile infection as an alternative to total colectomy in case of early failure of antimicrobial therapy. FMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings.

Conclusions: Faecal microbiota transplantation or transfer is a promising treatment for a variety of diseases in which the intestinal microbiota is disturbed. For indications other than C. difficile infection, more evidence is needed before more concrete recommendations can be made.

Ort, förlag, år, upplaga, sidor
Hoboken, USA: Wiley-Blackwell Publishing Inc., 2017
Nationell ämneskategori
Gastroenterologi Farmakologi och toxikologi
Identifikatorer
urn:nbn:se:oru:diva-53881 (URN)10.1111/apt.13868 (DOI)000389441900003 ()27891639 (PubMedID)2-s2.0-85002170778 (Scopus ID)
Anmärkning

Funding Agencies:

Seres Therapeutics

AbbVie

Astellas

Biogen

Janssen

MSD

Mundipharma

Takeda Summit Therapeutics

FalkFoundation

Takeda

Tillgänglig från: 2016-12-12 Skapad: 2016-12-12 Senast uppdaterad: 2019-03-26Bibliografiskt granskad
König, J., Holster, S., Bruins, M. & Brummer, R. J. (2017). Effective gluten degradation in non-coeliac gluten-sensitive subjects by Aspergillus Niger derived enzyme: A placebo-controlled randomized clinical trial. In: : . Paper presented at United European Gastroenterology (UEG) Week, Barcelona (Oct 28-Nov 1, 2017) (pp. A28). Sage Publications, 5, Article ID OP065.
Öppna denna publikation i ny flik eller fönster >>Effective gluten degradation in non-coeliac gluten-sensitive subjects by Aspergillus Niger derived enzyme: A placebo-controlled randomized clinical trial
2017 (Engelska)Konferensbidrag, Muntlig presentation med publicerat abstract (Refereegranskat)
Ort, förlag, år, upplaga, sidor
Sage Publications, 2017
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
urn:nbn:se:oru:diva-66300 (URN)10.1177/2050640617725668 (DOI)
Konferens
United European Gastroenterology (UEG) Week, Barcelona (Oct 28-Nov 1, 2017)
Tillgänglig från: 2018-04-03 Skapad: 2018-04-03 Senast uppdaterad: 2019-03-26Bibliografiskt granskad
Holster, S., Repsilber, D., Brummer, R. J. & König, J. (2017). Faecal microbiota transfer in irritable bowel syndrome – clinical outcomes of a randomised placebo- controlled trial. In: UEG Week 2017 Oral Presentations: . Paper presented at United European Gastroenterology (UEG) Week, Barcelona, Spain, October 28 - November 1, 2017 (pp. A155-A156). Sage Publications, 5
Öppna denna publikation i ny flik eller fönster >>Faecal microbiota transfer in irritable bowel syndrome – clinical outcomes of a randomised placebo- controlled trial
2017 (Engelska)Ingår i: UEG Week 2017 Oral Presentations, Sage Publications, 2017, Vol. 5, s. A155-A156Konferensbidrag, Muntlig presentation med publicerat abstract (Refereegranskat)
Ort, förlag, år, upplaga, sidor
Sage Publications, 2017
Serie
United European Gastroenterology Journal, ISSN 2050-6406, E-ISSN 2050-6414
Nationell ämneskategori
Gastroenterologi
Forskningsämne
Medicin
Identifikatorer
urn:nbn:se:oru:diva-66283 (URN)10.1177/2050640617725668 (DOI)
Konferens
United European Gastroenterology (UEG) Week, Barcelona, Spain, October 28 - November 1, 2017
Tillgänglig från: 2018-04-03 Skapad: 2018-04-03 Senast uppdaterad: 2019-04-02Bibliografiskt granskad
Holster, S., Brummer, R. J., Repsilber, D. & König, J. (2017). Fecal Microbiota Transplantation in Irritable Bowel Syndrome and a Randomized Placebo-Controlled Trial. In: 2017 DDW Abstracts: . Paper presented at Digestive Disease Week (DDW), Chicago, IL, USA, May 6-9, 2017 (pp. S101-S102). Saunders Elsevier, 152(5)
Öppna denna publikation i ny flik eller fönster >>Fecal Microbiota Transplantation in Irritable Bowel Syndrome and a Randomized Placebo-Controlled Trial
2017 (Engelska)Ingår i: 2017 DDW Abstracts, Saunders Elsevier, 2017, Vol. 152, nr 5, s. S101-S102Konferensbidrag, Muntlig presentation med publicerat abstract (Övrigt vetenskapligt)
Ort, förlag, år, upplaga, sidor
Saunders Elsevier, 2017
Serie
Gastroenterology, ISSN 0016-5085, E-ISSN 1528-0012
Nationell ämneskategori
Gastroenterologi
Identifikatorer
urn:nbn:se:oru:diva-66294 (URN)10.1016/S0016-5085(17)30679-0 (DOI)000403140300297 ()
Konferens
Digestive Disease Week (DDW), Chicago, IL, USA, May 6-9, 2017
Tillgänglig från: 2018-04-03 Skapad: 2018-04-03 Senast uppdaterad: 2019-05-06Bibliografiskt granskad
König, J., Holster, S., Maaike, B. & Brummer, R. J. (2017). Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting. Scientific Reports, 7(13100)
Öppna denna publikation i ny flik eller fönster >>Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting
2017 (Engelska)Ingår i: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 7, nr 13100Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The Aspergillus niger-derived prolyl endoprotease (AN-PEP) has previously been shown to degrade gluten in healthy subjects when added to an intragastrically infused meal. The current study investigated the efficacy of AN-PEP in a physiological meal setting. In this randomized placebo-controlled crossover study, 18 gluten-sensitive subjects consumed a porridge containing 0.5 g gluten together with two tablets either containing a high or low dose of AN-PEP, or placebo. Gastric and duodenal content was sampled over 180 minutes, and areas under the curve of gluten concentrations were calculated. The primary outcome, i.e. success rate of high dose AN-PEP defined as at least 50% gluten degradation compared to placebo in the duodenum, was achieved in 10 of 13 comparisons. In the stomach, gluten levels were reduced from 176.9 (median, interquartile range 73.5–357.8) to 22.0 (10.6–50.8, p = 0.001) in the high dose and to 25.4 μg × min/ml (16.4–43.7, p = 0.001) in the low dose. In the duodenum, gluten levels were reduced from 14.1 (8.3–124.7) in the placebo to 6.3 (3.5–19.8, p = 0.019) in the high dose and to 7.4 μg × min/ml in the low dose (3.8–12.0, p = 0.015). Thus even in a physiological meal setting, AN-PEP significantly degraded most gluten in the stomach before it entered the duodenum.

Ort, förlag, år, upplaga, sidor
Nature Publishing Group, 2017
Nyckelord
Gluten
Nationell ämneskategori
Näringslära
Forskningsämne
Näringslära
Identifikatorer
urn:nbn:se:oru:diva-61493 (URN)10.1038/s41598-017-13587-7 (DOI)000412950900035 ()29026170 (PubMedID)2-s2.0-85031294461 (Scopus ID)
Anmärkning

Funding Agency:

DSM

Tillgänglig från: 2017-10-12 Skapad: 2017-10-12 Senast uppdaterad: 2017-11-10Bibliografiskt granskad
Organisationer
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0003-0466-1861

Sök vidare i DiVA

Visa alla publikationer